Evidence map›Paper›PMID 37404070›Full record

Trial reportJournal of managed care & specialty pharmacy2023

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.

Matthew R Smith, Shahneen Sandhu, Daniel J George, Kim Nguyen Chi, Fred Saad, Antoine Thiery-Vuillemin, Olaf Stàhl, David Olmos, Daniel C Danila, Rustem Gafanov and 10 more

Open access · greenAbstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 4 countries.

Matthew R SmithHematology-Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston.
Shahneen SandhuMedical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Australia.
Daniel J GeorgeMedical Oncology, Duke University School of Medicine, Duke Cancer Institute, Durham, NC.
Kim Nguyen ChiDivision of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada.
Fred SaadCentre Hospitalier de L'université de Montréal, Université de Montréal, Montréal, Québec, Canada.
Antoine Thiery-VuilleminMedical Oncology Department, Centre Hospitalier Régional Universitaire Besancon - Hôpital Jean Minjoz, Besancon, France.
Olaf StàhlDepartment of Oncology, Skåne University Hospital, Lund, Sweden.
David OlmosDepartment of Medical Oncology, Spanish National Cancer Research Centre, Madrid, Spain.
Daniel C DanilaMedical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
Rustem GafanovMedical Oncology, Russian Scientific Center of Roentgenology and Radiology, Moscow.
Elena CastroGenitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Spain, now with Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.
Helen MoonHematology-Oncology, Kaiser Permanente Southern California, Riverside.
Anthony M JoshuaMedical Oncology Department, Kinghorn Cancer Centre, St. Vincent's Hospital Sydney, Darlinghurst, Australia.
Gary E MasonClinical Oncology, Janssen Research & Development, LLC, Spring House, PA.
Byron M EspinaClinical Oncology, Janssen Research & Development, LLC, Los Angeles, CA.
Yan LiuJanssen Global Commercial Strategy Organization, Horsham, PA, now with Genmab US, Plainsboro, NJ.
Angela Lopez-GitlitzClinical Oncology, Janssen Research & Development, LLC, Los Angeles, CA.
Peter FrancisJanssen Research & Development, LLC, Raritan, NJ.
Katherine B BevansJanssen Global Commercial Strategy Organization, Horsham, PA, now with Genmab US, Plainsboro, NJ.
Karim FizaziMedical Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Hospital Clínico Universitario Virgen de la Victoria · ESJanssen (United States) · USMemorial Sloan Kettering Cancer Center · USSkåne University Hospital · SEUniversité Paris-Saclay · FR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantQuality of LifeDNAFemaleHumansIndazolesMalePiperidinesDNAIndazolesniraparibPiperidines

Identifiers

PMID37404070
PMCPMC10387937
OpenAlexW4383186570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.